These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 26378933)

  • 21. Early tumor-cell gene expression changes may predict the response to first-line bortezomib-based therapy in patients with newly diagnosed multiple myeloma.
    Liapis K; Kastritis E; Bagratouni T; Vassiliou S; Papachristidis A; Charitaki E; Alevizopoulos N; Harhalakis N; Terpos E; Delimpasi S; Dimopoulos MA
    J BUON; 2015; 20(5):1314-21. PubMed ID: 26537080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
    Balsas P; Galán-Malo P; Marzo I; Naval J
    Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
    Chang H; Trieu Y; Qi X; Xu W; Stewart KA; Reece D
    Leuk Res; 2007 Jun; 31(6):779-82. PubMed ID: 16996589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bortezomib-based regimens improve the prognosis of newly diagnosed MM patients with chromosomal aberrations except for del(17q13): A retrospective study from a single center.
    Liu Z; Zeng Q; Xiang B
    Medicine (Baltimore); 2021 May; 100(18):e25834. PubMed ID: 33950994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
    Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
    Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma.
    Koksal IT; Sanlioglu AD; Karacay B; Griffith TS; Sanlioglu S
    Urol Oncol; 2008; 26(2):158-65. PubMed ID: 18312935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response.
    Hofman IJF; van Duin M; De Bruyne E; Fancello L; Mulligan G; Geerdens E; Garelli E; Mancini C; Lemmens H; Delforge M; Vandenberghe P; Wlodarska I; Aspesi A; Michaux L; Vanderkerken K; Sonneveld P; De Keersmaecker K
    Leukemia; 2017 Aug; 31(8):1706-1714. PubMed ID: 27909306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms underlying the increased chemosensitivity of bortezomib-resistant multiple myeloma by silencing nuclear transcription factor Snail1.
    Huang Z; Liang X; Wu W; Chen X; Zeng Q; Yang M; Ge J; Xia R
    Oncol Rep; 2019 Jan; 41(1):415-426. PubMed ID: 30365089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
    Chen MH; Qi C; Reece D; Chang H
    Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy.
    Bouralexis S; Findlay DM; Atkins GJ; Labrinidis A; Hay S; Evdokiou A
    Br J Cancer; 2003 Jul; 89(1):206-14. PubMed ID: 12838325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells.
    Sanlioglu AD; Karacay B; Koksal IT; Griffith TS; Sanlioglu S
    Cancer Gene Ther; 2007 Dec; 14(12):976-84. PubMed ID: 17853923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging trends in the clinical use of bortezomib in multiple myeloma.
    Richardson PG; Schlossman R; Mitsiades C; Hideshima T; Munshi N; Anderson K
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):84-8. PubMed ID: 16231845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window.
    Koschny R; Ganten TM; Sykora J; Haas TL; Sprick MR; Kolb A; Stremmel W; Walczak H
    Hepatology; 2007 Mar; 45(3):649-58. PubMed ID: 17326159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
    Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
    Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
    Röhn TA; Wagenknecht B; Roth W; Naumann U; Gulbins E; Krammer PH; Walczak H; Weller M
    Oncogene; 2001 Jul; 20(31):4128-37. PubMed ID: 11464279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.
    Smith MR; Jin F; Joshi I
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5528s-5534s. PubMed ID: 17875785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
    Georgakis GV; Li Y; Humphreys R; Andreeff M; O'Brien S; Younes M; Carbone A; Albert V; Younes A
    Br J Haematol; 2005 Aug; 130(4):501-10. PubMed ID: 16098063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
    Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
    Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia.
    Conticello C; Adamo L; Vicari L; Giuffrida R; Iannolo G; Anastasi G; Caruso L; Moschetti G; Cupri A; Palumbo GA; Gulisano M; De Maria R; Giustolisi R; Di Raimondo F
    Acta Haematol; 2008; 120(1):19-30. PubMed ID: 18716397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).
    Rashid MBMA; Toh TB; Hooi L; Silva A; Zhang Y; Tan PF; Teh AL; Karnani N; Jha S; Ho CM; Chng WJ; Ho D; Chow EK
    Sci Transl Med; 2018 Aug; 10(453):. PubMed ID: 30089632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.